STOCK TITAN

Allarity Therapeutics swaps $3M debt for preferred stock

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(High)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

Allarity Therapeutics, Inc. (ALLR) completed an exchange with Streeterville Capital, LLC on November 16, 2026, issuing 3,000 Series B preferred shares for cancellation of a partitioned $3,000,000 portion of its A-1 Note; the note's outstanding balance fell by $3,000,000. Allarity received no cash proceeds. The shares have an aggregate initial stated value of $3,150,000, rank senior to common stock for dividends and liquidation distributions, and are not convertible into common stock. They accrue a 9% annual preferred return, compounded daily, payable quarterly in cash or, at Allarity's election, additional preferred shares.

Under a separate agreement, Streeterville consented to future at-the-market (ATM) sales but may revoke its consent. For each week with settled ATM sales, Allarity must pay Streeterville 33% of net proceeds; Streeterville may apply the payment to preferred-share redemption, repayment of the A-1 Note, or both. Following a specified Event of Default, the return rises to 15% per annum, and holders may elect a one-time 15% increase in stated value. Separately, Allarity expanded its ongoing Phase 2 stenoparib trial in advanced ovarian cancer to include patients with primary platinum-refractory disease and patients whose disease is clinically evaluable but not measurable under standard RECIST; the added groups will be evaluated separately.

0 points · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

0 major · 2 points

Hollow bars mark forward-looking points. How the balance works

Positive

  • None.

Negative

  • Moderate pointSeries B's 9% annual preferred return accompanies senior priority over common.
  • Moderate point. Forward-looking: it has not happened yet and may not happen.Future ATM sales require a 33% weekly net-proceeds payment to Streeterville.

Filing Explained

While preferred shares remain outstanding, specified financing and corporate actions face restrictions and holder-consent requirements.

The Certificate of Designation took effect on November 12, 2026; after the shares were issued on November 16, 2026, its terms made specified corporate actions subject to preferred-holder protections and restrictions.

A majority of the Series B holders must consent to amendments or repeal of the designation and to issuing stock that ranks equally with or ahead of Series B. While any Series B shares remain outstanding, the designation also generally restricts additional debt or equity, certain asset actions, specified reverse splits and defined fundamental transactions; a reverse split connected to a Nasdaq deficiency notice is excepted.

Series B has no general voting rights with the common stock, and the board may choose to redeem some or all of the preferred shares for cash under the designation.

Item 1.01 Entry into a Material Definitive Agreement Business
The company signed a significant contract such as a merger agreement, credit facility, or major partnership.
Item 3.02 Unregistered Sales of Equity Securities Securities
The company sold equity securities in a private placement or other unregistered transaction.
Item 3.03 Material Modification to Rights of Security Holders Securities
A change was made that materially affects the rights of existing shareholders (e.g., dividend rights, voting rights).
Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year Governance
The company amended its charter documents, bylaws, or changed its fiscal year.
Item 8.01 Other Events Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
A-1 Note balance reduction $3,000,000 Reduction upon the exchange of the partitioned note for Series B preferred shares.
Exchange shares issued 3,000 shares Series B preferred shares issued to Streeterville in the exchange.
Aggregate initial stated value $3,150,000 Stated value of the 3,000 Exchange Shares.
Series B shares designated 5,000 shares Shares of the new Series B preferred stock designated by the Certificate of Designation.
Preferred return 9% per annum Accrues on stated value and is compounded daily.
ATM Sweep Payment 33% of net proceeds Payable to Streeterville for each week with ATM sales settled.
Preferred return after Event of Default 15% per annum Rate following a specified Event of Default.
One-time stated-value increase after Event of Default 15% The Required Holders may elect this increase following a specified Event of Default.
Stated Value financial
"initial stated value of $1,050 (the “Stated Value”)"
Stated value is an accounting figure a company assigns to a share when the share has no par (legal) value; it becomes the portion of proceeds recorded as the company’s permanent capital for regulatory and bookkeeping purposes. It matters to investors because it affects the equity reported on the balance sheet and the legal limits on distributions or dividend payments, but it is not the market price — think of it as a record-keeping sticker price rather than what buyers actually pay.
Preferred Return financial
"accrues a preferred return on its Stated Value at a rate of 9% per annum"
Preferred return is a minimum annual return that certain investors are promised before the manager or owner shares in profits; think of it as the first slice of earnings that gets paid out like a priority lane. It matters to investors because it reduces downside risk and sets a performance benchmark — managers only earn their performance-based share after this preferred amount is delivered, so it affects expected cash flow timing and alignment of incentives.
Event of Default financial
"may elect to declare an Event of Default upon specified covenant, payment or share-issuance defaults"
An event of default is a specific breach of a loan or bond agreement—such as missed payments or breaking agreed rules—that gives lenders the legal right to act, for example by demanding immediate repayment, seizing collateral, or accelerating other obligations. For investors, it’s a red flag because it can sharply reduce a company’s ability to operate or raise money, like a car lender repossessing a vehicle after missed payments, and often leads to falling share or bond prices.
at-the-market offering financial
"sales of Common Stock under any future at-the-market offering facility"
An at-the-market offering is a method companies use to sell new shares of stock directly into the open market over time, rather than all at once. This allows them to raise money gradually, similar to selling small pieces of a product instead of a large batch. For investors, it means the company can access funding more flexibly, but it may also increase the supply of shares and influence the stock’s price.
platinum-refractory medical
"patients with primary platinum-refractory disease"
A cancer described as platinum-refractory does not respond to platinum-based chemotherapy drugs (like cisplatin or carboplatin) or stops responding quickly after treatment. For investors, this is important because patients with platinum-refractory disease have limited standard options, creating clear unmet medical need and potential market opportunity for new therapies; think of it like a lock that no longer opens with a commonly used key, so new keys (treatments) are needed.
Response Evaluation Criteria in Solid Tumors medical
"not measurable under standard Response Evaluation Criteria in Solid Tumors"
Standardized rules used in clinical trials to measure how solid tumors change after treatment—whether they shrink, grow, or stay the same—based on imaging and predefined size thresholds. Investors care because these measurements determine whether a treatment shows meaningful benefit, influence regulatory approval chances, trial outcomes and market value, and act like a scorecard that converts medical effects into the data that drives commercial decisions.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How much debt did ALLR exchange for preferred stock?

Allarity exchanged a partitioned $3,000,000 portion of its A-1 Note for 3,000 Series B preferred shares, reducing the note's outstanding balance by $3,000,000. The shares had an aggregate initial stated value of $3,150,000. Allarity received no cash proceeds, and Streeterville provided no consideration beyond surrendering and canceling the partitioned note.

What return do ALLR's Series B preferred shares pay?

They accrue a 9% annual preferred return on stated value, compounded daily, payable quarterly within five trading days after quarter-end in cash or, at Allarity's election, additional Series B preferred shares. Following a specified Event of Default, the preferred return increases to 15% per annum.

How are ALLR's future ATM proceeds shared with Streeterville?

For each week in which Allarity sells common stock under an ATM, it must pay Streeterville 33% of net proceeds from sales settled during that week. Streeterville may apply the payment to redeem its Series B preferred stock, repay the A-1 Note, or both. If Streeterville does not elect, the payment goes to preferred redemption unless that is barred by law or the Certificate of Designation.

Can ALLR redeem its Series B preferred stock?

Yes. At the Board's discretion and subject to the Certificate of Designation, Allarity may redeem all or part of the outstanding Series B preferred stock for cash at the Redemption Price. Notice is required within 10 trading days after the Board's determination, and redemption is completed on the third trading day after notice is delivered.

Can ALLR's Series B preferred stock convert into common shares?

No. The Certificate of Designation does not provide for conversion of the Series B preferred stock into common stock. The preferred shares also have no general voting rights and do not vote with common stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
false --12-31 0001860657 0001860657 2026-11-12 2026-11-12 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported) November 12, 2026

 

ALLARITY THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

 

Delaware   001-41160   87-2147982
(State or other jurisdiction
of incorporation)
  (Commission File Number)   (IRS Employer
Identification No.)

 

123 E Tarpon Ave,

Tarpon Springs, FL 34689

(Address of principal executive offices)

 

(401) 426-4664

(Registrant’s telephone number, including area code)

 

Not applicable

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, par value $0.0001 per share   ALLR   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

Item 1.01 Entry into a Material Definitive Agreement.

 

Exchange Agreement

 

On November 12, 2026, Allarity Therapeutics, Inc. (the “Company”) entered into an Exchange Agreement (the “Exchange Agreement”) with Streeterville Capital, LLC, a Utah limited liability company (“Streeterville”). The Exchange Agreement relates to the Company’s Promissory Note A-1, dated March 2, 2026, in the original principal amount of $10,930,000 (the “A-1 Note”), issued pursuant to the Notes Purchase Agreement, dated March 2, 2026, between the Company and Streeterville (the “Purchase Agreement”).

 

Pursuant to the Exchange Agreement, the Company and Streeterville agreed to partition a new promissory note in the principal amount of $3,000,000 (the “Partitioned Note”) from the A-1 Note and exchange the Partitioned Note for 3,000 shares (the “Exchange Shares”) of the Company’s Series B Preferred Stock, par value $0.0001 per share (the “Series B Preferred Stock”). The Exchange Agreement provides that the outstanding balance of the A-1 Note is reduced by $3,000,000. The partition became effective upon acceptance of the Certificate of Designation described below by the Secretary of State of the State of Delaware. The Partitioned Note is evidenced by the Exchange Agreement, without a separate note instrument.

 

On November 16, 2026, following the filing and effectiveness of the Certificate of Designation, the Company completed the exchange and issued the Exchange Shares to Streeterville in exchange for the surrender and cancellation of the Partitioned Note. The Company received no cash proceeds from the exchange, and Streeterville provided no consideration other than the surrender of the Partitioned Note. Except as modified by the Exchange Agreement, the existing transaction documents remain in effect.

 

Series B Preferred Stock

 

In connection with the exchange, the Company’s Board of Directors approved a Certificate of Designation of Preferences and Rights of Series B Preferred Stock (the “Certificate of Designation”) on November 12, 2026. The Certificate of Designation designated 5,000 shares of Series B Preferred Stock, each with an initial stated value of $1,050 (the “Stated Value”). The 3,000 Exchange Shares have an aggregate initial Stated Value of $3,150,000. The Certificate of Designation does not provide for conversion of the Series B Preferred Stock into shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”).

 

Each share of Series B Preferred Stock accrues a preferred return on its Stated Value at a rate of 9% per annum, compounded daily, from its issuance date (the “Preferred Return”). The Preferred Return is payable quarterly, within five trading days following the end of each calendar quarter, in cash or, at the Company’s election, in additional shares of Series B Preferred Stock. The number of additional shares is determined by dividing the accrued and unpaid Preferred Return by $1,050, with cash paid in lieu of fractional shares.

 

The Series B Preferred Stock ranks senior to the Common Stock and other junior capital stock with respect to dividends, distributions and payments upon liquidation, dissolution or winding up. Upon a liquidation, dissolution or winding up, each share is entitled to its then-applicable Stated Value plus accrued and unpaid Preferred Return, before any distribution to junior stockholders. After payment of that amount, the Series B Preferred Stock does not participate in remaining liquidation distributions and does not participate in dividends or distributions to holders of Common Stock. The Company may, at the discretion of its Board of Directors and subject to the Certificate of Designation, redeem all or a portion of the outstanding Series B Preferred Stock for cash at the same amount (the “Redemption Price”). Notice is required within ten trading days after the Board’s determination, and the redemption is to be completed on the third trading day after delivery of the notice.

 

1

 

 

The Series B Preferred Stock has no general voting rights and does not vote with the Common Stock. The Certificate of Designation requires the prior written consent of holders of a majority of the outstanding Series B Preferred Stock (the “Required Holders”) to amend or repeal the Certificate of Designation or to authorize or issue capital stock ranking senior to or pari passu with the Series B Preferred Stock as to the specified preferences.

 

While any Series B Preferred Stock remains outstanding, the Certificate of Designation imposes covenants that include maintaining the Company’s Exchange Act reporting status and a listing or quotation of the Common Stock on Nasdaq, the New York Stock Exchange or NYSE American. Subject to the terms and exceptions in the Certificate of Designation and the Side Letter described below, it also restricts additional issuances of debt or equity securities, changes to authorized capital, pledges of assets, material asset dispositions outside the ordinary course of business, certain reverse stock splits, and the entry into or consummation of a Fundamental Transaction, as defined in the Certificate of Designation. That definition includes specified business combinations, reorganizations, transfers of material assets to affiliates and distributions to stockholders outside the ordinary course of business. The reverse-stock-split restriction contains an exception for a split in connection with satisfaction of a Nasdaq deficiency notice. Additional Series B Preferred Stock may be issued only to the initial holder or its affiliates or assignees. The Company also may not enter into agreements restricting transactions with, or issuances of securities to, holders of Series B Preferred Stock or their affiliates as specified in the Certificate of Designation.

 

The restrictions on additional debt and equity issuances generally cover debt obligations other than trade payables incurred in the ordinary course of business, equity securities, and securities convertible into or exchangeable for equity securities, with an exception for issuances or sales to a holder of Series B Preferred Stock or its affiliates. The Side Letter provides a separate conditional consent for certain at-the-market sales, as described below.

 

The Required Holders may elect to declare an Event of Default upon specified covenant, payment or share-issuance defaults that remain uncured for five trading days, or upon specified bankruptcy or insolvency events. Following an Event of Default, the Preferred Return increases to 15% per annum, and the Required Holders may elect a one-time 15% increase in the Stated Value. Holders also may pursue available remedies, including injunctive relief prohibiting issuances of Common Stock or preferred stock unless their Series B Preferred Stock is simultaneously redeemed in full at the Redemption Price.

 

Side Letter

 

On November 12, 2026, the Company and Streeterville also entered into a letter agreement regarding Conditional Consent to Future Use of ATM (the “Side Letter”). Under the Side Letter, Streeterville consents to sales of Common Stock under any future at-the-market offering facility (an “ATM”), notwithstanding the restriction on issuances in Section 10(e) of the Certificate of Designation. Streeterville may revoke the consent at any time by written notice. For each week in which the Company sells Common Stock under its ATM, the Company must pay Streeterville an amount equal to 33% of the net proceeds from all sales settled during that week (each, a “Sweep Payment”).

 

Streeterville may elect to apply a Sweep Payment, in whole or in part, to redemption of its Series B Preferred Stock at the Redemption Price, repayment of the outstanding balance of the A-1 Note, or both. In the absence of an election, a Sweep Payment is applied to redemption of Series B Preferred Stock unless that redemption is not permitted by applicable law or the Certificate of Designation. Once the A-1 Note is paid in full or Streeterville no longer holds Series B Preferred Stock, the entire Sweep Payment is applied to the other obligation. Upon request, the Company must report the number of shares sold and gross proceeds from ATM sales during the preceding week. Failure to make a Sweep Payment when due constitutes an event of default under the A-1 Note and the Certificate of Designation.

 

2

 

 

The Side Letter also provides that, for purposes of note exchanges under Section 1.7 of the Purchase Agreement, the value of the Series B Preferred Stock held by Streeterville, calculated as the number of shares multiplied by the Stated Value, is included in the aggregate outstanding balance of the A Notes. The Side Letter controls in the event of a conflict with the Certificate of Designation and does not otherwise waive provisions of the parties’ other agreements or defaults under those agreements.

 

The foregoing descriptions of the Certificate of Designation, Exchange Agreement and Side Letter do not purport to be complete and are qualified in their entirety by reference to the full text of those documents, copies of which are filed as Exhibits 3.1, 10.1 and 10.2, respectively, to this Current Report on Form 8-K and are incorporated herein by reference. The form of certificate representing the Series B Preferred Stock is filed as Exhibit 4.1 to this Current Report on Form 8-K.

 

Item 3.02 Unregistered Sales of Equity Securities.

 

The information set forth in Item 1.01 of this Current Report on Form 8-K regarding the exchange and issuance of the Exchange Shares is incorporated herein by reference. The Exchange Shares were issued in reliance upon the exemption from registration provided by Section 3(a)(9) of the Securities Act of 1933, as amended. The Exchange Shares were exchanged exclusively with an existing security holder of the Company for securities of the Company, and no commission or other remuneration was paid or given, directly or indirectly, for soliciting the exchange.

 

Item 3.03 Material Modification to Rights of Security Holders.

 

The information set forth in Items 1.01 and 5.03 of this Current Report on Form 8-K is incorporated herein by reference. Upon issuance of the Exchange Shares on the closing date described in Item 1.01, the rights of holders of Common Stock became subject to the senior preferences, protective provisions and covenants applicable to the Series B Preferred Stock, including its priority with respect to dividends, distributions and payments upon liquidation, dissolution or winding up, and the restrictions on specified issuances, capital changes and transactions described above.

 

Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

 

On November 12, 2026, the Company filed the Certificate of Designation with the Secretary of State of the State of Delaware, which became effective on November 12, 2026. The Certificate of Designation establishes the rights, preferences and limitations of a new series of 5,000 shares of Series B Preferred Stock from the Company’s authorized preferred stock. The information set forth in Item 1.01 of this Current Report on Form 8-K regarding the Certificate of Designation is incorporated herein by reference. A copy of the Certificate of Designation is filed as Exhibit 3.1 to this Current Report on Form 8-K and is incorporated herein by reference.

 

Item 8.01 Other Events.

 

On November 16, 2026, the Company issued a press release announcing an expansion of eligibility for its ongoing Phase 2 trial of stenoparib, a dual PARP and WNT pathway inhibitor, in advanced ovarian cancer to include patients with primary platinum-refractory disease and patients whose disease is clinically evaluable but not measurable under standard Response Evaluation Criteria in Solid Tumors. A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

 

3

 

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit
Number
  Description
3.1   Certificate of Designation of Preferences and Rights of Series B Preferred Stock of Allarity Therapeutics, Inc.
4.1   Form of Series B Preferred Stock Certificate.
10.1   Exchange Agreement, dated November 12, 2026, by and between Allarity Therapeutics, Inc. and Streeterville Capital, LLC.
10.2   Letter Agreement, dated November 12, 2026, by and between Allarity Therapeutics, Inc. and Streeterville Capital, LLC.
99.1   Press Release, dated November 16, 2026.
104   Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

4

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  Allarity Therapeutics, Inc.
     
Date: November 17, 2026 By: /s/ Thomas H. Jensen
    Thomas H. Jensen
Chief Executive Officer

 

5

 

Exhibit 99.1

 

Allarity Therapeutics Expands Phase 2 Stenoparib Trial to Three Ovarian Cancer Patient Cohorts

 

Investigator-supported move capitalizes on strong enrollment momentum and encouraging early clinical observations

 

Adds platinum-refractory patients as well as those with hard-to-measure but clinically evaluable disease

 

Leverages existing clinical sites to evaluate groups independently and accelerate potential paths to commercialization

 

TARPON SPRINGS, Fla., November 16, 2026 – Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)—a differentiated, dual PARP and WNT pathway inhibitor— today confirmed expanded eligibility for its ongoing Phase 2 trial in advanced ovarian cancer. This opens the study to patients with primary platinum-refractory disease and patients whose disease can be evaluated clinically but is not measurable under standard Response Evaluation Criteria in Solid Tumors (“RECIST”).

 

The expansion into additional patient populations was prompted by the enthusiasm of clinical investigators for the potential of stenoparib as a well-tolerated, oral treatment option for advanced ovarian cancer patients and reflects the encouraging early performance of the ongoing trial in platinum-resistant and platinum-ineligible patients. Importantly, the addition of these new patients now allows Allarity to build upon prior evidence of remarkable, durable clinical benefit in primary platinum-refractory disease while also evaluating stenoparib’s potential role across a broader spectrum of advanced ovarian cancer patients.

 

“We are excited about the expansion of eligibility to include patients with primary platinum-refractory disease as well as those with resistant but not measurable disease, allowing access to a potentially effective therapeutic agent among patients routinely excluded from clinical trial participation. We are hopeful that these patients will benefit from stenoparib and that we can learn more about best treatment options for all patients with ovarian cancer,” said Kathleen N. Moore, M.D., M.S., Principal Investigator of the Phase 2 stenoparib trial, Deputy Director and Director of Phase I Oncology Trials at the Fred & Pamela Buffett Cancer Center, and Professor in the Department of Obstetrics and Gynecology at the University of Nebraska Medical Center.

 

“We’re encouraged by the progress we’ve seen in the trial, and we’re excited to build on it,” said Thomas Jensen, Chief Executive Officer of Allarity Therapeutics. “The strategic expansion of patient eligibility in this trial allows us to efficiently map the potential of stenoparib across multiple high-unmet-need populations. A strong result in any one of the three groups could support further development. And if the data support development in more than one group, stenoparib could ultimately reach more patients and address a larger market.”

 

 

Allarity Therapeutics, Inc. | 123 E Tarpon Ave | Tarpon Springs, Florida | U.S.A. | NASDAQ: ALLR | www.allarity.com

Page 1 of 4

 

 

Earlier Findings Justify Broader Evaluation

 

The ongoing Phase 2 study builds on findings from earlier experience in the trial. In heavily pretreated patients with advanced, recurrent ovarian cancer, previously presented observations at the ESMO Gynaecological Cancers Congress in June 2026 included:

 

●Treatment Duration and Survival: In a patient with primary platinum-refractory disease, treatment duration was nearly 1 year with survival exceeding 2 years.

 

●Clinical Benefit: Extended clinical benefit in platinum-resistant ovarian cancer patients with BRCA-mutant and BRCA-wild-type disease, with some patients staying on drug nearly 2.5 years.

 

●Complete, Confirmed Response: An unprecedented response in a heavily pretreated platinum-resistant patient retreated with a PARP inhibitor.

 

●Median Overall Survival: A median Overall Survival (mOS) of 22 months in patients treated with stenoparib (this compares favorably to recent U.S. Food and Drug Administration (FDA) approved drugs showing mOS in similar patients of ~16 months).

 

Consistent with its long-standing clinical data reporting policy, Allarity will release clinical and scientific data at future scientific and clinical conferences.

 

About Allarity Therapeutics

 

Allarity Therapeutics, Inc. (NASDAQ: ALLR) is a clinical-stage pharmaceutical company focused on developing personalized cancer treatments. The Company is developing stenoparib, a novel PARP/tankyrase inhibitor for patients with advanced ovarian cancer, and is using its proprietary DRP® technology to develop a companion diagnostic designed to identify patients expected to derive the greatest clinical benefit from stenoparib. Allarity’s principal operations are located in Denmark, and its U.S. business address is in Florida. For more information, visit www.allarity.com.

 

About Stenoparib/2X-121

 

Stenoparib is an orally available, small-molecule dual-targeted inhibitor of PARP1/2 and tankyrase 1/2. Tankyrases have emerged as potential therapeutic targets in cancer due in part to their role in regulating the WNT signaling pathway. Aberrant WNT/β-catenin signaling has been implicated in the development and progression of numerous cancers, including drug-resistant cancers. Through its inhibition of PARP and the WNT signaling pathway, stenoparib has the potential to provide therapeutic benefit across multiple cancer types, including ovarian cancer, small cell lung cancer and colorectal cancer.

 

Allarity has secured exclusive global rights to develop and commercialize stenoparib, which was originally developed by Eisai Co., Ltd. and was formerly known as E7449 and 2X-121.

 

Under an earlier Phase 2 protocol evaluating stenoparib in patients with advanced ovarian cancer, Allarity observed promising and durable clinical benefit in patients with ovarian cancer who received two or more prior lines of therapy and were treated with stenoparib twice daily. Updated data from this earlier protocol were presented at the AACR Special Conference on Advances in Ovarian Cancer in September 2025. These analyses remain subject to change as the study data mature.

 

 

Allarity Therapeutics, Inc. | 123 E Tarpon Ave | Tarpon Springs, Florida | U.S.A. | NASDAQ: ALLR | www.allarity.com

Page 2 of 4

 

 

Based on the emerging clinical experience with stenoparib, Allarity developed a new protocol focused on patients with platinum-resistant ovarian cancer, which began enrolling patients in the summer of 2025. The previous protocol enrolls platinum-resistant or platinum-ineligible patients. Allarity has amended the protocol to add two patient groups that will be evaluated separately from the original cohort, namely patients with primary platinum-refractory disease and patients whose disease can be evaluated clinically but is not measurable under standard Response Evaluation Criteria in Solid Tumors (“RECIST”). The study is designed to advance the clinical development of stenoparib toward potential FDA approval.

 

In parallel, a separate Phase 2 trial evaluating stenoparib in combination with temozolomide for patients with relapsed small cell lung cancer, or SCLC, began enrolling in early 2026 and is currently enrolling patients at multiple U.S. Department of Veterans Affairs sites.

 

About the Drug Response Predictor – DRP® Companion Diagnostic

 

Allarity uses its drug-specific DRP® technology to identify patients who, based on the gene expression signature of their cancer, may be more likely to benefit from a particular drug. By screening patients before treatment, and selecting those with a sufficiently high, drug-specific DRP score, the DRP technology is designed to increase the likelihood of therapeutic benefit.

 

The DRP methodology is based on the comparisons of sensitive and resistant human cancer cell lines, and incorporates transcriptomic data, clinical tumor biology filters and prior clinical trial outcomes. The DRP uses messenger RNA expression profiles derived from patient biopsies to generate drug-specific predictive scores.

 

The DRP® platform has demonstrated the ability to provide statistically significant predictions of clinical outcome following drug treatment across dozens of retrospective and prospective clinical studies. The platform is designed for potential application across multiple cancer types, is patented for dozens of anti-cancer drugs and has been extensively described in peer-reviewed scientific literature.

 

Follow Allarity on Social Media

 

LinkedIn: https://www.linkedin.com/company/allaritytx/

 

 

Allarity Therapeutics, Inc. | 123 E Tarpon Ave | Tarpon Springs, Florida | U.S.A. | NASDAQ: ALLR | www.allarity.com

Page 3 of 4

 

 

Forward-Looking Statements

 

This press release contains forward-looking statements within the meaning of applicable federal securities laws. Forward-looking statements reflect current expectations or forecasts regarding future events. The words “anticipates,” “believes,” “continues,” “could,” “estimates,” “expects,” “intends,” “may,” “might,” “plans,” “possible,” “potential,” “predicts,” “projects,” “should,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include, but are not limited to, statements regarding continued enrollment and conduct of the Company’s ongoing Phase 2 trial of stenoparib in advanced ovarian cancer; the enrollment, treatment and evaluation of additional patient populations under the amended protocol; the interpretation and further evaluation of clinical observations and their potential relationship to findings from the earlier Phase 2 protocol; the potential clinical benefit of stenoparib, including treatment duration and survival outcomes; the potential for the additional patient populations to provide further clinical, regulatory or commercial development opportunities for stenoparib, including the potential to reach additional patients and address a larger market; the continued development and potential regulatory approval of stenoparib and its DRP® companion diagnostic; and the Company’s plans for future scientific presentations and clinical data disclosures, including the timing and scope of such disclosures. Any forward-looking statements in this press release are based on management’s current expectations of future events and are subject to multiple risks and uncertainties that could cause actual results to differ materially from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, risks related to delays or difficulties in patient enrollment, treatment, follow-up, data collection or analysis; the possibility that implementing the amendment may take longer or cost more than anticipated, or that using the existing trial infrastructure may not yield the expected efficiencies; the possibility that preliminary observations may change as additional data become available or following further review; the risk that current or future studies may not confirm findings from the earlier protocol or demonstrate sufficient safety or clinical benefit; the possibility that clinical outcomes in the additional patient populations may differ from prior observations or may not support broader clinical development, regulatory approval or commercial opportunities; differences in patient populations and study protocols that may limit comparisons; uncertainty regarding treatment duration and overall survival; the possibility that stenoparib or its DRP® companion diagnostic may not receive regulatory approval; changes or delays in scientific presentation or data disclosure plans, including those arising from data availability, conference acceptance or applicable embargo requirements; and the Company’s ability to secure sufficient financing and other resources to continue development. For a discussion of risks and uncertainties and other important factors that could cause actual results to differ materially from those contained in the forward-looking statements, see the risk factors and other disclosures in Allarity’s filings with the SEC, including its most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. These filings are available through the SEC’s website. All information in this press release is as of the date of the release, and the Company undertakes no obligation to update or revise this information, except as required by applicable law.

 

###

Company Contact:

 

investorrelations@allarity.com

 

 

Allarity Therapeutics, Inc. | 123 E Tarpon Ave | Tarpon Springs, Florida | U.S.A. | NASDAQ: ALLR | www.allarity.com

Page 4 of 4

 

Filing Exhibits & Attachments

8 documents

Keep reading